0002

Ildong Holdings Co., Ltd. (000230)

Market Closed
14 Feb, 06:30
KRX SM KRX SM
6,540. 00
+210
+3.32%
72.38B Market Cap
- P/E Ratio
400% Div Yield
39,877 Volume
- Eps
6.33K
Previous Close
Day Range
6,440 6,750
Year Range
5,470 12,220
Earnings results expected in 81 days

Summary

000230 closed yesterday higher at ₩6,540, an increase of 3.32% from Thursday's close, completing a monthly increase of 2.03% or ₩130. Over the past 12 months, 000230 stock lost -23.06%.
000230 is not paying dividends to its shareholders.
The last earnings report, released on Feb 06, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on May 07, 2025.
Ildong Holdings Co., Ltd. has completed 2 stock splits, with the recent split occurring on Mar 05, 2020.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on KRX SM (KRW).
Want to track 000230 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

000230 Chart

Ildong Holdings Co., Ltd. (000230) FAQ

What is the stock price today?

The current price is ₩6,540.00.

On which exchange is it traded?

Ildong Holdings Co., Ltd. is listed on KRX SM.

What is its stock symbol?

The ticker symbol is 000230.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 72.38B.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on May 07, 2025.

Has Ildong Holdings Co., Ltd. ever had a stock split?

Ildong Holdings Co., Ltd. had 2 splits and the recent split was on Mar 05, 2020.

Ildong Holdings Co., Ltd. Profile

Drug Manufacturers - Specialty & Generic Industry
Healthcare Sector
Dae-Chang Park CEO
KRX SM Exchange
KR7000230003 ISIN
KR Country
- Employees
- Last Dividend
5 Mar 2020 Last Split
- IPO Date

Overview

Ildong Holdings Co., Ltd., originally known as Ildong Pharmaceutical Co., Ltd. before its name change in August 2016, stands as a significant player in the pharmaceutical industry both within South Korea and on an international level. Founded in 1941 and headquartered in Seoul, South Korea, the company specializes in the development, manufacture, and supply of pharmaceutical products. Over the years, Ildong Holdings has diversified its offerings to include new drug development focused on combating resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing. Furthermore, the company extends its expertise to the research and production of health foods and ingredients, demonstrating its commitment to enhancing healthcare through innovation.

Products and Services

  • New Drug Development: Ildong Holdings is at the forefront of innovation, developing new drugs to address critical health issues like resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing. Their research and development efforts aim to provide groundbreaking treatments to improve patient outcomes globally.
  • Raw Vitamins, Probiotics, and Antimicrobials: The company manufactures essential health-enhancing products including raw vitamins to support overall health, probiotics for gut health, and antimicrobials to fight infections.
  • Biovita: A lactobacillus product developed by Ildong Holdings, Biovita promotes digestive health by maintaining gut flora balance, showcasing the company's dedication to probiotic solutions.
  • Aronamin: This multivitamin product is designed to meet daily health requirements by supplying essential nutrients, reflecting the company’s focus on preventative healthcare.
  • Health Foods and Ingredients Research and Manufacture: Ildong Holdings invests in the research and manufacture of health foods and ingredients, endorsing their vision for a healthier future through nutrition science.
  • Hyaluronic Acid for Medical and Cosmetic Use: The company provides high-quality hyaluronic acid, a key ingredient used in drugs, medical devices, and cosmetics, highlighting its versatility and importance in various industries.
  • Medical Devices and Healthcare Products Distribution: Through online platforms, Ildong Holdings distributes medical devices, quasi-drugs, health supplements, food products, beverages, cosmetics, sanitary ware, and other healthcare products, ensuring a wide reach to consumers and healthcare facilities.
  • Original and Generic Prescription Drugs Manufacturing: Engaging in the manufacturing of both original and generic prescription drugs positions Ildong Holdings as a crucial entity in the pharmaceutical supply chain, aimed at providing accessible medication options.
  • Pharmaceutical SI Consulting and Solutions: The company offers pharmaceutical SI consulting, system development and deployment, RFID and barcode systems, and other solutions, demonstrating its capability to innovate not just in products but also in services that enhance the efficiency of the pharmaceutical and healthcare industries.
  • Advertising Business: Ildong Holdings also engages in advertising business activities, showcasing its diverse interests and its ability to promote healthcare solutions effectively to the market.

Contact Information

Address: 2, Baumoe-ro 27-gil, Seoul, South Korea, 06752
Phone: 82 2 526 3114